Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02473224 · ClinicalTrials.gov registry record · Phase 1
Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies
A Phase 1 study of Gastroenteritis Norovirus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT02473224: Completed Phase 1 study of Gastroenteritis Norovirus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02473224 is a Phase 1 study of Gastroenteritis Norovirus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02473224, a Phase 1 study of Gastroenteritis Norovirus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, randomized, double blind, as well as partially blinded (for Cohort 4), placebo-controlled safety, illness, and infection study of a new experimental human challenge stock of the Norovirus genogroup II, genotype 2 (GII.2) isolate designated Snow Mountain virus (SMV). The study duration is 24 - 36 months. The primary objectives are to: 1) evaluate the safety and reactogenicity of the GII.2 Snow Mountain norovirus challenge stock and 2) determine a safe and optimal challenge dose of GII.2 Snow Mountain norovirus to achieve illness in a high proportion (= / \> 75%) of subjects.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Norovirus GII.2 Challenge
Study Locations (1)
Georgia
- Emory Vaccine Center - The Hope Clinic - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2018-11-27 |
| Phase | Phase 1 |
What the finished NCT02473224 record still lists
NCT02473224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Gastroenteritis Norovirus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02473224 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02473224 about?
NCT02473224 is a clinical study titled "Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies". This is a phase I, randomized, double blind, as well as partially blinded (for Cohort 4), placebo-controlled safety, illness, and infection study of a new experimental human challenge stock of the Norovirus genogroup II, genotype 2 (GII.2) isolate designated Snow Mountain virus (SMV). The study dura...
What is the current status of trial NCT02473224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2015-10-28. Estimated completion is 2018-11-27.
What conditions does trial NCT02473224 study?
This clinical trial studies the following conditions: Gastroenteritis Norovirus.
What interventions are being tested in trial NCT02473224?
The interventions under investigation include: Placebo (OTHER), Norovirus GII.2 Challenge (BIOLOGICAL).
Who is sponsoring clinical trial NCT02473224?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02473224 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroenteritis Norovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02473224's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI